CLINICAL TRIALS AND OBSERVATIONS Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy

نویسندگان

  • Andreas Hochhaus
  • Hagop M. Kantarjian
  • Michele Baccarani
  • Jeffrey H. Lipton
  • Jane F. Apperley
  • Brian J. Druker
  • Thierry Facon
  • Stuart L. Goldberg
  • Francisco Cervantes
  • Dietger Niederwieser
  • Richard T. Silver
  • Richard M. Stone
  • Timothy P. Hughes
  • Martin C. Muller
  • Rana Ezzeddine
  • Athena M. Countouriotis
  • Neil P. Shah
چکیده

1III. Medizinische Klinik, Medizinische Fakultät Mannheim, Universität Heidelberg, Mannheim, Germany; 2Department of Leukemia, M.D. Anderson Cancer Center, Houston, TX; 3Department of Hematology-Oncology “Seràgnoli,” S Orsola-Malpighi University Hospital, University of Bologna, Italy; 4Princess Margaret Hospital, Toronto, ON, Canada; 5Department of Haematology, Hammersmith Hospital, London, United Kingdom; 6Division of Hematology and Medical Oncology, Oregon Health Science University, Portland; 7Hópital Claude Huriez, Lille, France; 8Cancer Center, Hackensack University Medical Center, NJ; 9Department of Hematology, Hospital Clinic, Barcelona, Spain; 10Medizinische Klinik und Poliklinik II, Universitätsklinikum Leipzig, Germany; 11Weill Medical College of Cornell University, New York Presbyterian Hospital, New York, NY; 12Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, MA; 13Division of Hematology, Institute of Medical and Veterinary Science, Adelaide, Australia; 14Bristol-Myers Squibb, Wallingford, CT; 15Division of Hematology and Oncology, University College of San Francisco School of Medicine, CA

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

CLINICAL TRIALS AND OBSERVATIONS Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations

Secondary imatinib resistance in chronic myeloid leukemia (CML) is associated in approximately 50% of cases with mutations in the BCR-ABL kinase domain, necessitating switch to one of several new tyrosine kinase inhibitors (TKIs) that act differentially on mutated BCR-ABL. We assess here whether scoring mutation based on in vitro inhibitory concentration of each TKI-mutation pair can predict lo...

متن کامل

CLINICAL TRIALS AND OBSERVATIONS The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up

Responses can be achieved with dasatinib or nilotinib after failure of 2 prior tyrosine kinase inhibitors (TKIs). We report on 48 chronic myeloid leukemia patients sequentially treated with 3 TKIs: 34 with dasatinib after imatinib/nilotinib failure and 14 with nilotinib after imatinib/ dasatinib failure. Before the third TKI, 25 patients were in chronic phase (CP), 10 in accelerated phase (AP),...

متن کامل

CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Result of high-dose imatinib mesylate in patients with Philadelphia chromosome–positive chronic myeloid leukemia after failure of interferon-

Imatinib at 400 mg daily is effective in chronic-phase chronic myeloid leukemia (CML) after interferon failure, although only a few patients achieve a molecular remission. We investigated whether higher doses of imatinib may be more effective. Thirty-six patients with chronicphase CML after failure on interferonwere treated with 400 mg imatinib twice daily. Median time from diagnosis was 25 mon...

متن کامل

CLINICAL TRIALS AND OBSERVATIONS Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy

We assessed the long-term efficacy of imatinib dose escalation in 84 patients with chronic myeloid leukemia in chronic phase who met the criteria of failure to standard-dose imatinib. Twenty-one patients with hematologic failure and 63 with cytogenetic failure had their imatinib dose escalated from 400 to 800 mg daily (n 72) or from 300 to 600 mg daily (n 12). After a median follow-up of 61 mon...

متن کامل

CLINICAL TRIALS AND OBSERVATIONS Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase

1Clinical Research Centre, Centre Hospitalier et Universitaire (CHU) La Miletrie, Poitiers, France; 2Hammersmith Hospital, London, United Kingdom; 3St Mary’s Hospital, The Catholic University of Korea, Seoul, Korea; 4Department of Hematology and Bone Marrow Transplantation, British Hospital of Buenos Aires, Buenos Aires, Argentina; 5Istituto di Ematologica E Oncologica Medica, Policlinico S. Or...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره   شماره 

صفحات  -

تاریخ انتشار 2007